Biosimilars

Cornelis van Tilburg, ASCO 2019 – Larotrectinib in paediatric TRK fusion cancer

At the ASCO 2019 annual meeting, Cornelis van Tilburg discusses findings from recent studies investigating the efficacy and safety of larotrectinib in paediatric TRK fusion cancer patients (NCT02637687 and NCT02576431) and what this means for the future. Questions 1.What percentage of paediatric tumours have tropomyosin receptor kinase (TRK) fusions and in what tumour types are […]

The Impact of Biosimilars in Supportive Care in Cancer

European Oncology & Haematology. 2018;14(1):20–32 DOI: https://doi.org/10.17925/EOH.2018.14.1.20

Biosimilars, which are copies of patent-expired large-molecule biologic drugs (Table 1),1–8 offer the same rationale as generic drugs. They can give patients, hospitals and healthcare systems the opportunity to expand patient access to care and offer potential budget savings to reinvest (Table 2).1,2,9 They are designed to be similar in effectiveness, safety and quality to […]

Potential Solutions for Sustaining the Costs of Cancer Drugs

European Oncology & Haematology, 2017;13(2):102–7 DOI: https://doi.org/10.17925/EOH.2017.13.02.102

Introduction With the growing burden of cancer, sustainable solutions are urgently required to ensure access to effective and safe treatments for all patients.1 Health expenditure on cancer in Europe more than doubled between 1995 and 2014, increasing from €35.7 billion to €83.2 billion;2 high-cost cancer drugs are the main drivers of this increase in many […]

What Happens when the Cost of Cancer Care Becomes Unsustainable?

European Oncology & Haematology, 2017;13(2):108–13 DOI: https://doi.org/10.17925/EOH.2017.13.02.108

The estimated incidence of cancer increased by almost one third across Europe between 1995 and 2012, and this growth is predicted to continue.1,2 Compared with other diseases and disabilities, the lost years of life and productivity resulting from cancer represent a heavy drain on the global economy, especially in low- and middle-income countries, where the […]

Can we Continue to Afford Access to Cancer Treatment?

European Oncology & Haematology, 2017;13(2):114–9 DOI: https://doi.org/10.17925/EOH.2017.13.02.114

Innovation in healthcare is highly beneficial from a patient perspective; however, the introduction of new drugs, often at high cost, is placing increasing pressure on many healthcare systems.1 As a result, these systems are facing a growing crisis of affordability, both globally and locally, which is unsustainable. Oncology is the area of greatest concern. In […]

The need for supportive treatment with G-CSF in oncological therapy – Interview with Matti Aapro

Dr Matti Aapro, from our Editorial Board, discusses supportive treatment with granulocyte-colony stimulating factor (G-CSF) in chemo-sensitive tumors, and also guidelines for the prevention and treatment of febrile neutropenia.   Support: The filming of this video was supported by Accord Biopharmaceuticals.

Biosimilars in Oncology

Oncology & Hematology Review, 2016;12(1):22–8 DOI: https://doi.org/10.17925/OHR.2016.12.01.22

Cancer places a significant and growing burden on healthcare systems around the world; it is the second most common cause of death in the US and accounts for nearly one in four deaths.1 About 1,665,540 new cancer cases are expected in the US in 2014. While population growth and aging will increase the number of […]

Biomarkers for childhood relapsed ALL

Prof Moorman (Newcastle University, Newcastle, UK) talks to ecancertv at EHA 2015 about the importance of identifying biomarkers for childhood relapsed acute lymphoblastic leukaemia (ALL).

T cell therapy for children with aggressive leukaemia

T cell therapy for children with aggressive leukaemia